Extend Biosciences Inc.
Newton, MA
- UEI
- DZTKWESJQQ99
- CAGE
- 62TW2
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 90 Bridge St #100, Newton, MA 02458, USA
- Website
- extendbio.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Army sbir phase I | ACC Aberdeen Proving Ground | $161,589 | |
| First monthly technical report | ACC Aberdeen Proving Ground | $999,998 | |
| Scientific research services | ACC Aberdeen Proving Ground | $149,998 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Velum Inc. | Cambridge, MA | — |
| Microquin LTD | Cambridge, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Byomass Inc. | Sudbury, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Gentibio, Inc. | Cambridge, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Celdara Medical, LLC | Lebanon, NH | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Extend Biosciences Inc., a woman-owned small business based in Newton, Massachusetts, is a clinical-stage biotechnology company that operates as a prime recipient of federal research grants focused on peptide and protein therapeutic development, competing on a full-and-open basis across federal health and defense research programs.
Extend Biosciences' core capability centers on drug development using its proprietary D VITylation platform technology, which enhances the pharmacokinetic properties of peptides and proteins to extend their half-lives and reduce dosing frequency. The company's recent federal grant portfolio reflects this focus: a $839,497 award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420, performance period September 2026 through September 2027) to develop a long-acting ghrelin derivative as a novel therapeutic for amyotrophic lateral sclerosis; a National Institute of Diabetes and Digestive and Kidney Diseases grant (award date September 1, 2024, completion August 31, 2027) to advance a long-acting parathyroid hormone derivative (EXT608) through Phase I clinical development for hypoparathyroidism; and a Food and Drug Administration Office of Medical Products and Tobacco grant (award date September 15, 2023, completion February 28, 2026) supporting a Phase II clinical study of EXT608. All work is performed at Extend Biosciences' Newtonville, Massachusetts facility.
Extend Biosciences' customer base spans health research and defense. The National Institute of Diabetes and Digestive and Kidney Diseases accounts for three awards across the source portfolio, while the National Science Foundation has placed two awards. Army programs (Materiel Command Research Development and Engineering Command and Joint PEO Chemical and Biological Defense) together represent $1.1 million in combined potential value. The vendor operates exclusively as a prime recipient and has not pursued subcontracting roles; combined dollars obligated across all federal awards reach $21.6 million against a combined potential value of $1.3 million, indicating substantial prior grant commitments. Two awards face ultimate completion within the next twenty-four months and thus enter recompete windows in that window.
Quick answers
Is Extend Biosciences Inc. registered in SAM.gov?
Yes. Extend Biosciences Inc.'s SAM.gov registration is active through April 13, 2027.
What is Extend Biosciences Inc.'s CAGE code?
Extend Biosciences Inc.'s CAGE code is 62TW2, and its Unique Entity ID (UEI) is DZTKWESJQQ99.
What is Extend Biosciences Inc.'s most recent federal award?
Extend Biosciences Inc.'s most recent federal grant award is Development of a long-acting ghrelin derivative as a novel ALS therapeutic (HT9425261E466), from Defense Health Agency, on September 15, 2026.
On GovTribe
See Extend Biosciences Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors